Cardiothoracic & vascular anesthesia
Outcomes and Risk Factors in Vasoplegic Patients Following Left Ventricular Assist Device Implantation
Authors' conclusion
Vasoplegia following LVAD implantation is a common postoperative complication. Longer duration on cardiopulmonary bypass, preoperative renal dysfunction, and postoperative inotrope use following LVAD implantation were associated with an increased risk of developing postoperative vasoplegia.
Study context
- Population
- Adults undergoing HeartMate left ventricular assist device (LVAD) implantation, quaternary care academic medical centre, 2019 to 2022
- Participants
- 184 adults
- Outcome
- Incidence of vasoplegia (persistent hypotension requiring >0.2 μg/kg/min norepinephrine equivalent for >6 hours) after LVAD implantation
Methodological detailssingle-centre, multivariable logistic regression, subgroup analysis
- Single-centre
- Multivariable logistic regression
- Subgroup analysis
Main finding
As reported in the abstract
Incidence of vasoplegia
33%
Observational data: associations, not effects.
Further findings
Vasopressor use in patients with vasoplegia
- Median maximum vasopressor dose (norepinephrine equivalents), μg/kg/min
- 0.28 (0.24-0.34)
- Median duration on vasopressors, hours
- 30 (18-50)
Factors independently associated with vasoplegia (multivariable logistic regression)
- MAP immediately before the operating room, OR
- 0.961
- Duration on CPB, OR
- 1.012
- Preoperative renal dysfunction, OR
- 3.185
- Postoperative inotrope use, OR
- 4.857
Vasoplegia by preoperative renin-angiotensin-aldosterone system inhibitors (subgroup)
- No differences in rates of vasoplegia
Mortality, vasoplegia vs no vasoplegia
- No mortality differences
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →